Skip to main content
. Author manuscript; available in PMC: 2012 Apr 4.
Published in final edited form as: Leuk Res. 2010 Sep 15;35(3):310–316. doi: 10.1016/j.leukres.2010.06.010

Fig. 7.

Fig. 7

Comparison of bone marrow FLT uptake in normal subjects with that of AML patients pre-treatment. (Top) SUV distribution reveals similarity of normal marrow (blue) and marrow of CR patient pre-treatment (green), with almost all uptake in SUV<8 range. Distribution is quite different for RD patient (red) who displayed significant uptake in the SUV>8 range. (Bottom) At all SUV, the ratio of CR patient’s pre-treatment marrow to normal marrow uptake was approximately unity. At SUV > 8, RD patient’s pre-treatment marrow often displayed uptake over 100 times greater than that of normal marrow.